$ANIP
ANI Pharmaceuticals Inc Stock $anip

$anip Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000114420416099268 Filed on May 05, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2015 Q1
Revenue	$20.56M	$18.04M	$18.80M
YoY Change	9.34%	-14.27%	72.48%
Cost Of Revenue	$3.410M	$3.540M	$2.751M
YoY Change	23.95%	-3.54%	4.92%
Gross Profit	$17.15M	$14.50M	$16.05M
YoY Change	6.84%	-16.47%	93.89%
Gross Profit Margin	83.41%	80.4%	85.37%
Selling, General & Admin	$5.904M	$5.460M	$4.751M
YoY Change	24.27%	15.19%	28.3%
% of Gross Profit	34.44%	37.66%	29.6%
Research & Development	$966.0K	$660.0K	$403.0K
YoY Change	139.7%	15.79%	7.18%
% of Gross Profit	5.63%	4.55%	2.51%
Depreciation & Amortization	$4.609M	$2.110M	$1.327M
YoY Change	247.32%	64.84%	88.76%
% of Gross Profit	26.88%	14.55%	8.27%
Operating Expenses	$6.870M	$8.230M	$5.154M
YoY Change	33.29%	24.7%	26.35%
Operating Profit	$5.666M	$6.268M	$9.567M
YoY Change	-40.78%	-41.81%	173.73%
Interest Expense	-$2.782M	-$2.770M	-$2.725M
YoY Change	2.09%	246.25%
% of Operating Profit	-49.1%	-44.19%	-28.48%
Other Income/Expense, Net	$2.000K	$0.00	$68.00K
YoY Change	-97.06%	-100.0%	134.48%
Pretax Income	$2.886M	$3.500M	$6.910M
YoY Change	-58.23%	-65.21%	96.08%
Income Tax	-$1.540M	$630.0K	$2.541M
% Of Pretax Income	-53.36%	18.0%	36.77%
Net Earnings	$1.346M	$2.880M	$4.369M
YoY Change	-69.19%	-86.29%	30.07%
Net Earnings / Revenue	6.55%	15.97%	23.24%
Basic Earnings Per Share	$0.12	$0.25	$0.38
Diluted Earnings Per Share	$0.12	$0.25	$0.38
COMMON SHARES
Basic Shares Outstanding	11.40M shares		11.33M shares
Diluted Shares Outstanding	11.49M shares		11.56M shares

Balance Sheet

Concept	2016 Q1	2015 Q4	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.70M	$154.7M	$165.6M
YoY Change	-53.08%	-8.46%	222.18%
Cash & Equivalents	$77.75M	$154.7M	$165.6M
Short-Term Investments
Other Short-Term Assets	$1.300M	$1.500M	$9.300M
YoY Change	-86.02%	36.36%	1450.0%
Inventory	$13.90M	$13.39M	$10.74M
Prepaid Expenses		$1.453M	$1.546M
Receivables	$22.50M	$21.93M	$17.37M
Other Receivables	$1.100M	$1.200M	$0.00
Total Short-Term Assets	$116.6M	$192.6M	$203.0M
YoY Change	-42.56%	-1.23%	198.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.400M	$7.131M	$5.281M
YoY Change	59.06%	36.53%	16.89%
Goodwill	$1.838M	$1.838M	$1.838M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$147.4M	$66.40M	$45.41M
YoY Change	224.58%	57.84%	103.08%
Long-Term Investments
YoY Change
Other Assets	$17.40M	$17.30M	$10.50M
YoY Change	65.71%	12.34%
Total Long-Term Assets	$175.0M	$92.68M	$62.99M
YoY Change	177.79%	34.87%	119.36%
TOTAL ASSETS
Total Short-Term Assets	$116.6M	$192.6M	$203.0M
Total Long-Term Assets	$175.0M	$92.68M	$62.99M
Total Assets	$291.6M	$285.3M	$266.0M
YoY Change	9.63%	8.17%	175.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.040M	$2.066M	$2.288M
YoY Change	32.87%	-22.16%	-13.98%
Accrued Expenses	$1.727M	$617.0K	$1.897M
YoY Change	-8.96%	-51.38%	87.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.20M	$11.76M	$9.073M
YoY Change	78.55%	-11.16%	97.24%
LONG-TERM LIABILITIES
Long-Term Debt	$115.2M	$113.4M	$112.2M
YoY Change	2.67%	6.48%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$115.2M	$113.4M	$112.2M
YoY Change	2.67%	6.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.20M	$11.76M	$9.073M
Total Long-Term Liabilities	$115.2M	$113.4M	$112.2M
Total Liabilities	$131.4M	$125.2M	$121.2M
YoY Change	8.38%	4.52%	2535.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.504M	-$4.350M	-$15.36M
YoY Change	-64.16%	-77.95%	-65.96%
Common Stock	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$0.00
YoY Change			-100.0%
Treasury Stock Shares			2.500K shares
Shareholders Equity	$160.2M	$160.1M	$144.7M
YoY Change
Total Liabilities & Shareholders Equity	$291.6M	$285.3M	$266.0M
YoY Change	9.63%	9.9%	175.2%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2015 Q1
OPERATING ACTIVITIES
Net Income	$1.346M	$2.880M	$4.369M
YoY Change	-69.19%	-86.29%	30.07%
Depreciation, Depletion And Amortization	$4.609M	$2.110M	$1.327M
YoY Change	247.32%	64.84%	88.76%
Cash From Operating Activities	$10.97M	$4.700M	$1.120M
YoY Change	879.38%	-56.24%	-78.37%
INVESTING ACTIVITIES
Capital Expenditures	$1.369M	-$1.100M	$112.0K
YoY Change	1122.32%	223.53%	-5.08%
Acquisitions
YoY Change
Other Investing Activities	-$84.18M	$0.00
YoY Change
Cash From Investing Activities	-$85.55M	-$1.100M	-$4.612M
YoY Change	1754.97%	233.33%	-63.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.500M		$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$2.355M	180.0K	$18.00K
YoY Change	-13183.33%	-99.85%	-99.96%
NET CHANGE
Cash From Operating Activities	$10.97M	4.700M	$1.120M
Cash From Investing Activities	-$85.55M	-1.100M	-$4.612M
Cash From Financing Activities	-$2.355M	180.0K	$18.00K
Net Change In Cash	-$76.94M	3.780M	-$3.474M
YoY Change	2114.65%	-97.18%	-108.63%
FREE CASH FLOW
Cash From Operating Activities	$10.97M	$4.700M	$1.120M
Capital Expenditures	$1.369M	-$1.100M	$112.0K
Free Cash Flow	$9.600M	$5.800M	$1.008M
YoY Change	852.38%	-47.65%	-80.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	160082000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	285265000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	131410000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165681000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4350000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	291588000	USD
CY2016Q1	anip	Class C Special Stock Value ClassCSpecialStockValue	0	USD
CY2015Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164431000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5504000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	160178000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	125183000	USD
CY2016Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	115199000	USD
CY2015Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	113427000	USD
CY2016Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4632000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	722000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1188000	USD
CY2016Q1	anip	Accrued Medicaid Rebates AccruedMedicaidRebates	3424000	USD
CY2015Q4	anip	Accrued Medicaid Rebates AccruedMedicaidRebates	4631000	USD
CY2016Q1	us-gaap	Revenues Revenues	20555000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	17397000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	17316000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	147386000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	66397000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	1838000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	1838000	USD
CY2016Q1	us-gaap	Assets Assets	291588000	USD
CY2015Q4	us-gaap	Assets Assets	285265000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3040000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2066000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1727000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	617000	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	3410000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4609000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	14889000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	5666000	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2782000	USD
CY2015Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	606000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1327000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4612000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3955000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1000000	USD
CY2016Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	84182000	USD
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4500000	USD
CY2015Q1	anip	Increase Decrease Accrued Medicaid Rebates IncreaseDecreaseAccruedMedicaidRebates	-187000	USD
CY2015Q1	us-gaap	Revenues Revenues	18799000	USD
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	2751000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	966000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	403000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5904000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4751000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	9232000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	9567000	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2725000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	68000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	1346000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	4369000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1105000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	568000	USD
CY2016Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-81000	USD
CY2015Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	294000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1725000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1683000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	549000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	74000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	535000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3219000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-201000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-437000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	889000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-471000	USD
CY2016Q1	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	-466000	USD
CY2015Q1	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	-835000	USD
CY2016Q1	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-23000	USD
CY2015Q1	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-3772000	USD
CY2016Q1	anip	Increase Decrease Accrued Medicaid Rebates IncreaseDecreaseAccruedMedicaidRebates	-1207000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1369000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	112000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	144000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9000	USD
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	1000	USD
CY2015Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	9000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-76937000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3474000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169037000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165563000	USD
CY2016Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1643000	USD
CY2015Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6029000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	85000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	105000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	10969000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1120000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-85551000	USD
CY2016Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	143750000	USD
CY2016Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	25455000	USD
CY2016Q1	us-gaap	Long Term Debt LongTermDebt	115199000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4600000	shares
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	17394000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	17039000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	17039000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	16557000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	66179000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4400000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	USD
CY2016Q1	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.15	pure
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2355000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	18000	USD
CY2015Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	143750000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	27016000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	113427000	USD
CY2016Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3096000	USD
CY2015Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3307000	USD
CY2016Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1078000	USD
CY2015Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1078000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1562000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1481000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	211000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	211000	USD
CY2016Q1	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	47000	USD
CY2015Q1	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	9000	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	10648000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	10192000	USD
CY2016Q1	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	784000	USD
CY2015Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	998000	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	503000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	456000	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2232000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1897000	USD
CY2016Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	245000	USD
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	156000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4667000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4450000	USD
CY2016Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	47000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	147386000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	13630000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	13586000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2886000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6910000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1540000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2541000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2500000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited interim condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, accruals for chargebacks, Medicaid rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, deferred taxes and valuation allowance, and the depreciable lives of long-lived assets. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100000	USD
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.534	pure
CY2015Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.368	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	500000	shares
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2804000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2761000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1346000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	4369000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1339000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4346000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1339000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	4346000	USD
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	94000	shares
CY2015Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	236000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11489000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11562000	shares
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2016Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000	shares
CY2015Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2016Q1	us-gaap	Inventory Gross InventoryGross	14167000	USD
CY2015Q4	us-gaap	Inventory Gross InventoryGross	13543000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13082000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14493000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11581000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10101000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	161879000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	76498000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	13178000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2015Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	9000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11395000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11326000	shares
CY2015Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	400000	USD
CY2015Q1	anip	Accrued Royalties Assumed In Asset Purchase AccruedRoyaltiesAssumedInAssetPurchase	0	USD
CY2016Q1	anip	Accrued Royalties Assumed In Asset Purchase AccruedRoyaltiesAssumedInAssetPurchase	1199000	USD

Files In Submission

Name	View Source	Status
0001144204-16-099268-index-headers.html	Edgar Link	pending
0001144204-16-099268-index.html	Edgar Link	pending
0001144204-16-099268.txt	Edgar Link	pending
0001144204-16-099268-xbrl.zip	Edgar Link	pending
anip-20160331.xml	Edgar Link	completed
anip-20160331.xsd	Edgar Link	pending
anip-20160331_cal.xml	Edgar Link	unprocessable
anip-20160331_def.xml	Edgar Link	unprocessable
anip-20160331_lab.xml	Edgar Link	unprocessable
anip-20160331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v437620_10q.htm	Edgar Link	pending
v437620_ex10-1.htm	Edgar Link	pending
v437620_ex10-2.htm	Edgar Link	pending
v437620_ex31-1.htm	Edgar Link	pending
v437620_ex31-2.htm	Edgar Link	pending
v437620_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIP
ANI Pharmaceuticals Inc Stock $anip

2016 Q1 Form 10-Q Financial Statement

#000114420416099268 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP ANI Pharmaceuticals Inc Stock $anip

2016 Q1 Form 10-Q Financial Statement

#000114420416099268 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP
ANI Pharmaceuticals Inc Stock $anip